Intratect

Human normal immunoglobulin, the active ingredient in Intratect, is an immunoglobulin presented as an intravenous solution for infusion use. It provides passive immunity by supplying pooled IgG antibodies and is used in patients with primary immunodeficiency and certain immune‑mediated conditions.

GNH USA supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and clinics worldwide, with rigorous quality assurance and cold‑chain logistics.

Intratect, a human normal immunoglobulin, is used in conditions requiring replacement of IgG antibodies.

- Primary immunodeficiency diseases: restores IgG levels and reduces infection frequency. - Immune thrombocytopenic purpura (ITP): increases platelet counts and mitigates bleeding risk. - Kawasaki disease: reduces coronary artery aneurysm development. - Chronic inflammatory demyelinating polyneuropathy (CIDP): improves muscle strength and functional ability. - Guillain‑Barré syndrome: accelerates recovery of motor function.

Intratect may cause a range of adverse reactions following infusion.

Common Side Effects: - Headache: mild to moderate pain often occurring during or after infusion. - Fever and chills: transient rise in body temperature and shivering. - Fatigue: feeling of tiredness that may last several hours. - Nausea: mild gastrointestinal upset. - Infusion-related reactions: flushing, erythema, or itching at the site. - Hypertension: temporary increase in blood pressure.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: formation of blood clots in veins or arteries. - Renal failure: acute kidney injury, especially with high-dose regimens. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells leading to anemia. - Severe hypotension: sudden drop in blood pressure causing dizziness or collapse.

Prior to initiating Intratect therapy, clinicians should assess patient risk factors and monitor for potential complications.

- Screen for IgA deficiency: patients with anti‑IgA antibodies are at increased risk of anaphylaxis. - Monitor renal function: adjust dosing in patients with existing kidney impairment. - Assess thrombotic risk: avoid use in individuals with active hypercoagulable states. - Evaluate pregnancy and lactation status: use only if benefits outweigh potential risks. - Observe for infusion reactions: start with a slow infusion rate and increase gradually. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other medications and vaccines, requiring careful management.

Major Interactions (Avoid): - Live attenuated vaccines: may reduce vaccine efficacy; avoid concurrent administration. - High‑dose aspirin or other antiplatelet agents: increased risk of bleeding complications. - Cytotoxic chemotherapy: may alter drug clearance and increase toxicity.

Moderate Interactions (Monitor Closely): - Corticosteroids: may enhance overall immunosuppressive effect. - Rituximab: can affect B‑cell recovery and IgG levels. - Estrogen‑containing contraceptives: may increase thrombotic risk when combined with IVIG.